Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial

  title={Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial},
  author={Samir Jaber and Catherine Paugam and Emmanuel Futier and Jean Yves Lefrant and Sigismond Lasocki and Thomas Lescot and Julien Pottecher and Alexandre Demoule and Martine Ferrandiere and Karim Asehnoune and Jean Dellamonica and Lionel J. Velly and Paer-Selim Abback and Audrey de Jong and Vincent Brunot and Fouad Belafia and Antoine Roquilly and G{\'e}rald Chanques and Laurent Muller and Jean Michel Constantin and H{\'e}l{\'e}na Bertet and Kada Klouche and Nicolas Molinari and Boris Jung and Marion Monnin and J. M. Delay and Moussa Ciss{\'e} and Marie Geniez and Matthieu Conseil and Bruno Souche and Jean Michel Constantin and Eric Noll and Elise Morawiec and Alexandre Robert and Thibaut Triglia and Malika Mechati and Jean-Michel Arnal and J Durand-gasselin and Didier Demoly and Sami Hraiech and Laurent Papazian and Vincent Gilles and Thomas R. Rimmele and B{\'e}atrice Riu and Pierre Cougot and Olivier Fourcade and Philippe Seguin and Jonathan Charbit and Xavier Capdevila and Marc Leone and Laurent Zieleskiewicz and Carole Ichai and Jean-Christophe Orban and Micha{\"e}l Darmon and {\'E}lie Azoulay and Virginie Lemiale and Lara Zafrani and Karim Debbat and Oliver Mimoz and Claude Gu{\'e}rin and Eric Kipnis},
  journal={The Lancet},

Figures and Tables from this paper

Incidence and management of metabolic acidosis with sodium bicarbonate in the ICU: An international observational study
Early metabolic acidosis is common in critically ill patients and early administration of sodium bicarbonate is administered by clinicians to more severely ill patients but without correction for weight or acidosis severity, which warrants further investigation.
Effectiveness of Sodium Bicarbonate Infusion on Mortality in Critically Ill Children With Metabolic Acidosis
SB infusion does not reduce the in-hospital mortality of severely ill children with metabolic acidosis and increases the risk of hypernatraemia, hypokalaemia, and hypocalcaemia.
Early pH Change Predicts Intensive Care Unit Mortality
The rate of change in pH may better predict ICU mortality than other metabolic indices.
Patients with Severe Lactic Acidosis in the Intensive Care Unit: A Retrospective Study of Contributing Factors and Impact of Renal Replacement Therapy
The analysis confirms the high mortality rate of patients with SLA and adds that odds for mortality is even higher in patients who were started on RRT versus not, and suggests keeping an open mind to the factors that may influence the decision to start dialysis.
Bicarbonate Therapy for Critically Ill Patients with Metabolic Acidosis: A Systematic Review
The current literature suggests limited benefit from bicarbonate therapy for patients with severe metabolic acidosis (pH < 7.1 and bic carbonate < 6 mEq/L), however, biccarbonate therapy does yield improvement in survival for patientsWith accompanying acute kidney injury.
Bicarbonate Therapy in Renally Compromised Critically Ill Patients with Metabolic Acidosis: Study of Clinical Outcomes and Mortality Rate
Bicarbonate therapy was not found to affect the mortality rate in critically ill renally compromised patients with metabolic acidosis in Rawalpindi, Pakistan.
Effectiveness of sodium bicarbonate infusion on mortality in septic patients with metabolic acidosis
It was observed that SB infusion was not associated with improved outcome in septic patients with metabolic acidosis, but it was associated with improved survival in sepsis patients with AKI stage 2 or 3 and severe acidosis.


Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial.
To determine whether early initiation of RRT in patients who are critically ill with AKI reduces 90-day all-cause mortality, a single-center randomized clinical trial of 231 critically ill patients with KDIGO stage 2 found that more patients in the early group recovered renal function by day 90.
Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit.
In a trial involving critically ill patients with severe acute kidney injury, a delayed strategy averted the need for renal-replacement therapy in an appreciable number of patients and found no significant difference with regard to mortality.
Effect of Sodium Bicarbonate Administration on Mortality in Patients with Lactic Acidosis: A Retrospective Analysis
Lactic acidosis, which has a high mortality rate, should be evaluated in patients with metabolic acidosis and sodium bicarbonate should be prescribed with caution in the case of lactic Acidosis because sodium bICarbonate administration may affect mortality.
Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: A prospective, controlled clinical study
Administration of sodium bicarbonate did not improve hemodynamic variables in patients with lactic acidosis, but did not worsen tissue oxygenation.
Sodium bicarbonate supplements for treating acute kidney injury.
There is an urgent need for well conducted RCTs in this area and no RCT evidence - supportive or otherwise - for the use of sodium bicarbonate for people with AKI is found.
Bicarbonate therapy in the treatment of septic shock: a second look
Infusion of sodium bicarbonate in septic patients with arterial hyperlactatemia may facilitate weaning from mechanical ventilation and reduce length of ICU stay.
Use of base in the treatment of acute severe organic acidosis by nephrologists and critical care physicians: results of an online survey
The results of this survey indicate that the decisions whether to use base for the treatment of acute severe metabolic acidosis, and under which circumstances, vary among physicians, and indicate the need for further studies to develop evidence-based guidelines for therapy.
Lactic Acidosis: Current Treatments and Future Directions.
  • J. Kraut, N. Madias
  • Biology, Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2016
In animal studies, selective NHE1 inhibitors improve cardiovascular function, ameliorate lactic acidosis, and reduce mortality, supporting future research into their possible use in humans.